RA
KPTI icon

Rise Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Rise Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-131
Closed -$857 – 816
2025
Q3 		$857 Buy
+131
New +$705 ﹤0.01% 1303

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Rise Advisors's KPTI Position: Q4 2025 in Review

Rise Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 131 shares — an estimated $857 sold.

Rise Advisors first reported a position in KPTI in Q3 2025 and held it in 1 quarter. The position peaked at $857 in Q3 2025. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Rise Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 131 Karyopharm Therapeutics shares in Q4 2025, an estimated $857.
  • Rise Advisors first reported a position in Karyopharm Therapeutics in Q3 2025 and held it in 1 quarter.
  • Rise Advisors's Karyopharm Therapeutics position peaked at $857 in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.